46 results
6-K
EX-99.8
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
).
Mission
In accordance with articles 7:180 and 7:191 and 7:193 of the Code of companies and associations (hereinafter ‘CCA’), in our capacity as statutory … the justification of the issuance price.
Basis for the conclusion
We carried out our mission in accordance with the normative framework applicable
6-K
EX-99.6
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by-laws.
Responsibilities of the statutory auditor
In the context of our mission and in accordance with the Belgian standard (version revised 2020 … have at our disposition during the performance of our mission.
Statement related to independence
Our audit firm and our network did not provide
6-K
EX-99.1
GLPG
Galapagos NV
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
are convinced that we are taking the right steps to deliver on our core mission: adding years of life and improving the quality of life of patients globally … 2022. Our core mission in the field is to broaden patient access and improve clinical outcomes by bringing best-in-class medicines to patients
6-K
EX-99.1
GLPG
Galapagos NV
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
believe that Galapagos has the fundamentals in place to deliver on its mission to transform the lives of patients across the globe, while creating value
6-K
EX-99.1
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
of Directors,” said Mr. Dickinson. “I look forward to working with the team and to contributing to the company’s mission of pioneering on behalf of patients
6-K
EX-99.1
kw56ssuh7cb
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
oh68tev
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
6-K
EX-99.1
2lvjeajmx9 y5
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
EX-99.1
qc99zx5xlo xm
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
vhyjs429a5z6j
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
e20lb
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
qxtwoccm95l2
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.1
jkw9kou4
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
nclmvm3u60s74prc0
28 Apr 22
Current report (foreign)
4:06pm
6-K
EX-99.3
444wfl46
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
56w2gyupt3 w3
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
x3teng98m1k a4jnvwxe
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.15
2jewd7mor 8r1tk
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.2
y3e9xg
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.2
vam2w
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm